Rapid Dose Therapeutics Appoints Chief Financial Officer and Provides Business Update
BURLINGTON, ON, April 10, 2019 /CNW/ - Rapid Dose Therapeutics Corp. ("RDT" or the "Company") (CSE: DOSE), a Canadian leader in drug delivery solutions, is pleased to announce that Mr. Ian Fodie has been appointed Chief Financial Officer effective immediately. Mr. Fodie replaces Mr. Lino Fera, as part of the planned transition process following the Company's public listing in December 2018.
Mr. Fodie graduated from the University of Otago, New Zealand, with a Bachelor of Commerce degree, obtained his professional designation from the New Zealand Institute of Chartered Accountants, and has now resided in Canada for over 30 years. Most recently, Mr. Fodie acted as the CFO of Green Growth Brands Ltd. His experience also includes CFO of First Bauxite Corporation and Lithium Americas Corp., President & CEO of Oriental Minerals Inc. (now Woulfe Mining Corp.), and CFO of Longview Capital Partners Inc. (now Resinco Capital Partners Inc.).
"Ian brings a wealth of international accounting, financial, operations, and capital markets experience to RDT," stated Mark Upsdell, President and CEO. "On behalf of the board and management of RDT, I would like to welcome Ian to the team."
"It is with mixed emotions to see Lino leave — I would like to thank him for his many valuable contributions to the Company and wish him the best of luck as he pursues his charitable passions as co-founder of Cribwolf Foundation," added Mark Upsdell.
Business Update:
RDT is pleased to announce that the Company is currently in the final inspection and certification stages relating to the delivery of two of its proprietary Quickstrip™ production systems, which are expected to be operational by the end of April 2019.
RDT is also currently in the process of setup and certification of three additional QuickStrip™ production systems for the Company's growing list of global cannabis clients.
About Rapid Dose Therapeutics
Rapid Dose Therapeutics Corp. is a publicly-traded Canadian company that provides innovative, proprietary drug delivery technologies designed to improve outcomes and quality of lives, which offers Quick, Convenient, Precise and Discreet™ choices to consumers. RDT is focused and committed to clinical research and product development for the healthcare manufacturing industry — including nutraceutical, pharmaceutical and cannabis industries. Within the cannabis sector, RDT provides a turn-key Managed Strip Service Program which enables RDT's QuickStrip™ proprietary drug delivery technology to be licensed by select partners. RDT's service based annuity contracts drive recurring revenue which enables rapid expansion into emerging markets — generating value for consumers and shareholders. Rapid Dose Therapeutics is committed to continually create innovative solutions aimed at multiple consumer segments and future market needs — including humans, animals and plants.
For more information, visit: www.rapiddose.ca
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release may contain forward-looking information within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward- looking statements. Forward looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend" or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in respect of the delivery of products using the QuickStrip™ product delivery method, express, as at the date of this news release, the plans, estimates, forecasts, projections, expectations or beliefs of RDT as to future events or results and are believed to be reasonable based on information currently available to them. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
SOURCE Rapid Dose Therapeutics Inc.
For inquiries please contact: Mark Upsdell, President and Chief Executive Officer, Rapid Dose Therapeutics Inc., [email protected]; Ali Mahdavi, Managing Director, Spinnaker Capital Markets Inc., [email protected], (416) 962-3300
Share this article